Lucicebtide (ST101)
Glioblastoma (GBM)
Phase 2Active
Key Facts
About Sapience Therapeutics
Sapience Therapeutics is a private, clinical-stage biotech focused on developing peptide-based oncology drugs against challenging targets. The company's core technology involves two proprietary peptide platforms: SPEARs™ for intracellular targets and SPARCs™ for extracellular targets. Its lead asset, lucicebtide (formerly ST101), is a C/EBPβ antagonist in Phase 2 for glioblastoma (GBM), while ST316, a first-in-class β-catenin antagonist, is in Phase 2 for colorectal cancer and other solid tumors. The company is actively presenting clinical data at major oncology conferences and has received FDA Orphan Drug Designation for ST316 in Familial Adenomatous Polyposis (FAP).
View full company profileTherapeutic Areas
Other Glioblastoma (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| DB102 (Enzastaurin) | Denovo Biopharma | Phase 3 |
| GlioGuard Therapeutic & Diagnostic System | GlioGuard | Pre-clinical |
| DOC1021 | Diakonos Oncology | Phase 2 |
| Lead CAR-T Program | Kiragen Bio | Pre-clinical |
| GBM Immunotherapy (with SandboxAQ) | iOncologi | Pre-clinical |
| DCVax®-L | Northwest Biotherapeutics | Phase 3 |
| Glioblastoma Assay Optimization (CPRIT Grant) | SingleCell Biotechnology | Pre-clinical |
| Lead Program (unspecified) | BlueHaven Therapeutics | Preclinical |
| TLX101 (Pixclara® / 131I-IPA) | Telix Pharmaceuticals | Phase 3 |
| Paxalisib | Kazia Therapeutics | Phase II/III |